<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254641</url>
  </required_header>
  <id_info>
    <org_study_id>H-17004362</org_study_id>
    <nct_id>NCT03254641</nct_id>
  </id_info>
  <brief_title>Calciotropic Effects After hCG Stimulation Test</brief_title>
  <official_title>Calciotropic Effects After hCG Stimulation Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Blomberg Jensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have in a pilot study found that serum calcium levels change in response to hCG&#xD;
      stimulation test. We observed that serum calcium level measured at baseline and 72 hours&#xD;
      after hCG stimulation were different in men with gonadal insufficiency referred for this&#xD;
      stimulation test. Now we want to investigate a large cohort of men referred for hCG&#xD;
      stimulation test due to suspected impaired gonadal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      hCG signals through the LHCGR receptor and is know to stimulate testosterone production. hCG&#xD;
      stimulation tests are therefore used to evaulate the capacity of the testis to respond to&#xD;
      LH/hCG and thereby determine the degree og gonadal insufficiency and need for testosterone&#xD;
      supplementation. Some groups have found LHCRG in extragondal tissues indicating a direct&#xD;
      effect of hCG/LH outside the gonads. We noticed that some men with gonadal insuffciency had a&#xD;
      low calcium level after hCG stimulation test. Now we would like to investigate whether this&#xD;
      putative effect on calcium homeostasis of hCG is due to a direct effect or an indirect effect&#xD;
      through testosterone or other sex steroids that also change in response to hCG stimulation.&#xD;
      Moreover, we would like to clarify whether the chnage in calcium is compensated by classical&#xD;
      regulators such as PTH, 1,25OH2D3, calcitonin, phosphate, CTX, alkaline phosphatase or other&#xD;
      factors.&#xD;
&#xD;
      Aim of study:&#xD;
&#xD;
      The purpose of this study is to describe changes in calcium and calciotropic hormones after&#xD;
      hCG stimulation test&#xD;
&#xD;
      DESIGN This is a prospective observational study&#xD;
&#xD;
      Patients and methods 100 men referred for hCG stimulation test due to suspected gonadal&#xD;
      insuffciency age 18-60 years at Department of growth and reproduction, Rigshospitalet&#xD;
&#xD;
      Exclusion criteria are&#xD;
&#xD;
      intake of high dose calcium (above 1 mg daily) Known Disorders related to calcium metabolism,&#xD;
      hypercalcemia, Granulomatous disease such as Wegener, tuberculosis, etc,&#xD;
&#xD;
      SAMPLE SIZE CALCULATION AND STATISTICS By using a test level of 5% (level of significance),&#xD;
      power of 80% and at least 100 men completing the trial will enable us to detect a change in&#xD;
      calcium of 10%, and a change in serum PTH of 30%.&#xD;
&#xD;
      SCREENING AND TIME COURSE Men referred for hCG stimulation test at ourDepartment will be&#xD;
      screened for eligibility to the study. Those who meet the criteria for participation will be&#xD;
      informed, and if they consent allocated to the study.&#xD;
&#xD;
      Each person will have one blood sampling performed prior to the test and 72 and 96 hours&#xD;
      after the test.&#xD;
&#xD;
      Blood samples Venus blood is drawn preoperatively before hCG administration, 72 and 96 hours&#xD;
      after. Serum will be send for analysis within 45 minutes and the rest frozen within 1 hour&#xD;
      and will be stored at minus 20 degrees celsius until analysis.&#xD;
&#xD;
      OUTCOME MEASUREMENTS&#xD;
&#xD;
      Primary endpoints&#xD;
&#xD;
      â€¢Changes in total, albumin corrected and ionized calcium&#xD;
&#xD;
      Main Secondary endpoints&#xD;
&#xD;
        -  Changes in PTH&#xD;
&#xD;
        -  Changes in 1,25OH2D3&#xD;
&#xD;
        -  Changes in Phosphate&#xD;
&#xD;
        -  Changes in FGF23&#xD;
&#xD;
        -  Changes in Calcitonin&#xD;
&#xD;
        -  Changes in LHCGR in serum&#xD;
&#xD;
        -  Changes in Cortisol&#xD;
&#xD;
        -  Changes in total and free testosterone&#xD;
&#xD;
        -  Changes in total and free estradiol&#xD;
&#xD;
        -  Changes in kidney function (GFR/creatinin)&#xD;
&#xD;
        -  Changes in gonadotropins&#xD;
&#xD;
        -  Changes in 25OHD, 24,25OH2D3&#xD;
&#xD;
        -  Changes in serum concentrations of putative regulators and downstream signals&#xD;
           osteocalcin, osteopontin, RANKL, osteoprotegerin (OPG), alpha Klotho, Sclerostin and&#xD;
           IGF-1.&#xD;
&#xD;
      Temporal changes in serum level of binding proteins. differences for vitamin D binding&#xD;
      protein, albumin and sex hormone binding globulin.&#xD;
&#xD;
      Predefined subgroups orchiectomized men/ bilaterally irradiated testis High versus low&#xD;
      baseline estradiol/testosterone Low/high calcium/PTH baseline&#xD;
&#xD;
      ANALYSIS AND INTERVENTION&#xD;
&#xD;
      Reproductive hormones and growth factors will be analysed at dept. of GR, Rigshospitalet.&#xD;
      Other serum analyses will be analysed at Department of clinical biochemistry, and Aarhus&#xD;
      Kommune Hospital&#xD;
&#xD;
      ETHICS AND SIDE EFFECTS All the patients will have full-filled their investigation, before&#xD;
      they are invited to the study. They will be informed of potential adverse effects, and they&#xD;
      can leave the trial at any point without any consequences. This study poses no additional&#xD;
      risk to the patients except for the blood samples as everything else is according to standard&#xD;
      clinical practice.&#xD;
&#xD;
      PUBLICATION OF RESULTS All results, positive or negative will be submitted to peer reviewed&#xD;
      scientific journals. Data will successively be obtained and transferred to a statistical&#xD;
      database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in total, albumin corrected or ionized calcium</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
    <description>mmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25OH2D3</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortisol</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total and free testosterone</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total and free estradiol</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin, Shbg, VDBP</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25OHD or 24,25OH2D3</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone factors such as CTX, osteocalcin, RANKL, FGF23</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LHCGR</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
    <description>in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>72 and 96 hours after hCG injection</time_frame>
    <description>eGFR/creatinine</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">242</enrollment>
  <condition>Hypogonadism, Male</condition>
  <arm_group>
    <arm_group_label>hypogondal men</arm_group_label>
    <description>men referred for hCG stimulation test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>5000 IE times one</description>
    <arm_group_label>hypogondal men</arm_group_label>
    <other_name>hCG</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        men with suspected gonadal i suffciency ofter after orchiectomy or bilateral irradiation&#xD;
        due to testis cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - men aged 18-60 years referred for hCG stimulation test due to previous treatment for&#xD;
        testis cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  high intake calcium&#xD;
&#xD;
          -  know disorders in calcium homeostasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>referred for hCG stimulation test</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Growth and Reproduction, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Martin Blomberg Jensen</investigator_full_name>
    <investigator_title>MD, group leader</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>share all available data through danish data archive</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>2 years after study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

